



# 2018 National Preferred Formulary Update

# Building on our momentum: 2018 formulary updates



# National Preferred Formulary — FY 2017

## Savings to State of Delaware

**\$3,963,723**

in FY2017 savings  
tied to formulary  
exclusions

**95**

TOTAL EXCLUSIONS


**3.1%**

MEMBER IMPACT

**10.6%**

MEMBERS PURSUED A  
CLINICAL EXCEPTION

# 2018 NPF status changes



## MEMBER IMPACT

0.91%


(902 patients)  
Preferred/  
nonpreferred  
to excluded

0.12%

(122 patients)  
Preferred to  
nonpreferred

# Reducing costs and preserving clinically appropriate options

## NPF 2018 — TOTAL MARKET PRODUCTS



Savings achievable by excluding **ONLY 4%** of products including **46 MULTI-SOURCE BRANDS**

# New 2018 NPF exclusions

Therapy classes	Medications	
	Exclusions/ Member Impacts	Alternatives
<b>Granulocyte Stimulants</b> Blood cell Deficiency	Neupogen/2 patients	Granix, Zarxio
<b>Narcotic Analgesics (Oral)</b> Pain/inflammation	Opana ER (withdrawn from market)/7 patients	hydromorphone ER, morphine sulfate ER, oxymorphone ER, Hysingla ER, Nucynta ER, Oxycontin
	Oxycodone HCL ER/21 patients	
<b>Ophthalmic NSAIDs</b> Ophthalmic conditions	Nevanac/3 patients	bromfenac sodium, diclofenac sodium, ketorolac, tromethamine, Ilevro, Prolensa

# New 2018 NPF Exclusions

Medications		
Therapy classes	Exclusions/ Member Impacts	Alternatives
<b>Parathyroid Hormone</b> Osteoporosis	Forteo/9 patients	alendronate sodium, ibandronate sodium (oral & IV), risedronate sodium, zoledronic acid, Tymlos
<b>Phosphate Binders</b> Kidney Disease	Fosrenol/1 patient Renagel/1 patient	sevelamar, Phoslyra, Velporo
<b>Epinephrine Auto-injector</b> Anaphylaxis	epinephrine auto- injector (by A-S Medications, Impax, & Lineage)/142 patients	epinephrine auto-injector (by Mylan), Epipen, Epipen Jr.
<b>Estrogen</b> <b>Vaginal Disorders</b>	Femring/1 patient	Estradiol patches/tablets, yuvafem, Estrace cream, Estring, Premarin cream/tablets

# New 2018 NPF exclusions

Medications		
Therapy classes	Exclusions/ Member Impacts	Alternatives
<b>Glaucoma</b>	Timoptic/4 patients	timolol maleate, betaxolol HCL, levobunolol HCL, Alphagan P, Combigan
<b>Irritable Bowel Syndrome</b> GI disorders	Trulance/13 patients	Amitiza, Linzess
<b>Gastrointestinal</b> Heartburn/ulcer disease	Aciphex Sprinkles/1 patient Prevacid Solutab/19 patients Protonix Susp/3 patients	esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, Nexium Packets



# Multi-Source brand exclusions – new for 2018

The generic equivalent of these brand-name medicines are covered under your plan. FDA approved generic medicines meet strict FDA standards and contain the same active ingredients as their corresponding brand-name medicines, although they may have a different color or shape.

ABILIFY	LEXAPRO	SEROQUEL, SEROQUEL XR
ACIPHEX	LIBRAX	SINGULAIR
ADDERALL	LIDODERM	STRATTERA
ANDROGEL 1%	LOVENOX	TIKOSYN
ANUSOL-HC	LUNESTA	TOBI SOLUTION
ATACAND, ATACAND HCT	MINASTRIN 24 FE	TRIBENZOR
AZOR	NASONEX	VALIUM
BENICAR, BENICAR HCT	PLAQUENIL	VALTREX
BUPAP	PLAVIX	VYTORIN
CYMBALTA	PREVACID	WELLBUTRIN SR
CYTOMEL	PRISTIQ	XANAX, XANAX XR
EFFEXOR XR	PROTONIX	XENAZINE
IMITREX	PROVIGIL	ZEGERID
INDERAL LA	PROZAC	ZETIA
INTUNIV	PULMICORT RESPULES	ZOLOFT
		ZYFLO CR

# 2018 Preferred to Non-Preferred Changes

Therapy classes	Medications	
	NonPreferred/ Member Impacts	Preferred Alternatives
Anticoagulant	Pradaxa/39 patients	Eliquis, Xarelto
Insulins Diabetes	Basaglar Kwikpen/20 patients	Lantus Solostar, Levemir Flextouch, Toujeo Solostar, Tresiba Flextouch
Ophthalmic Anti-inflammatory	FML S.O.P./5 patients	dexamethasone sodium phosphate, fluoromethalone, prednisolone sodium phosphate, Lotemax
Skin Conditions	Condylox 0.5% Gel/7 patients	podofilox, imiquimod

# 2018 Preferred to Non-Preferred Changes

	Medications	
Therapy classes	NonPreferred/ Member Impacts	Preferred Alternatives
Prostate Cancer	Lupron Depot/1 patient	Eligard, Firmagon
Rectal Disorders	Proctofoam-HC/35 patients	hc pramoxine, pramcort
Cancer	Trexall/5 patients	methotrexate
Vitamins & Minerals	VitafoI-OB/1 patient	generic prenatal vitamins

# 2018 Preferred to Non-Preferred Changes

Therapy classes	Medications	
	NonPreferred/ Member Impacts	Preferred Alternatives
Pain/Inflammation	Zorvolex/5 patients	diclofenac potassium, diclofenac sodium
	<p>Additionally 6 drugs will move from non-preferred to preferred status on 1/1/18 for a positive impact for 28 patients for State of Delaware</p>	

# Communications plan



# Robust communication plan

